Trial Search Results
Intermittent Theta-Burst Stimulation to Target Irritability in Adults With ASD
This study aims to demonstrate the feasibility, tolerability, safety and preliminary efficacy of 6 weeks of fMRI-guided iTBS delivered to personalized regions of the prefrontal cortex (PFC) in adults with ASD in reducing irritability in adults with ASD.
Stanford is currently not accepting patients for this trial.
- Device: Intermittent theta-burst stimulation (iTBS)
1. Diagnosis of ASD or Asperger's based on DSM-5 criteria as confirmed by a qualified
clinician (including Dr. Fung), and if necessary the administration of Autism
Diagnostic Interview-Revised (ADI-R) and/or Autism Diagnostic Observation
2. Age 22 to 55.
3. Adults who are physically healthy.
4. No significant current psychosocial stressors per history.
5. Full scale IQ > 50.
6. ABC-I score of 18 or greater.
7. if the participant is taking medication, they must be stable on this medication
regiment for at least 4 weeks prior to baseline and agree to stay on these medications
for the duration of the trial
(f) Pre-term birth (<34 weeks' gestation) (g) Low birth weight (<2000 g). (h) DSM-5
diagnosis of other severe psychiatric disorder such as bipolar disorder or schizophrenia.
(i) Current use of benzodiazepines. (j) Use of other medications that modulate the GABA(A)
receptor within 4 weeks of scanning (8 weeks for fluoxetine).
(k) History of alcoholism or substance abuse. (l) Active medical problems such as unstable
seizures, congenital heart disease, endocrine disorders.
(m) Significant sensory impairments such as blindness or deafness. (n) Contraindication for
MRI. (o) Pregnancy. (p) evidence of genetic syndrome.
Ages Eligible for Study
22 Years - 55 Years
Genders Eligible for Study